Pharmacodynamics News and Research

RSS

FDA accepts IND application to initiate human clinical trial to evaluate BNC

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company's second product, bisnorcymserine (BNC).

3 Dec 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today that it will present new data at the inaugural CPRIT Innovations in Cancer Prevention and Research Conference, November 17-19, 2010 in Austin, TX.

17 Nov 2010

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

8 Nov 2010

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Alder Biopharmaceuticals Inc. today announced that data from two clinical studies of its ALD518 investigational antibody therapeutic will be presented at the Annual Meeting of the American College of Rheumatology in Atlanta.

8 Nov 2010

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.

7 Nov 2010

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

OptiNose Inc. announced the results from an analysis comparing the Phase II clinical trial obtained with its novel delivery technology to that of other formulations. The analysis suggests rapid absorption rate alone may not explain the efficacy in migraines treated with sumatriptan delivered with the Company's novel bi-directional technology. The results will be presented at the 2nd European Headache and Migraine Trust International on 28th of October 2010.

30 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

ViroPharma Incorporated today announced that it has completed enrollment in its Phase 2 study evaluating subcutaneous delivery of Cinryze™ (C1esterase inhibitor [human]). This multi-center, open-label, multi-dose Phase 2 study is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze in adolescent and adult subjects with hereditary angioedema (HAE).

25 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.

11 Oct 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

FerroKin BioSciences initiates international Phase 2 study of FBS0701

FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.

10 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

8 Sep 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Pharmacodynamics News and Research

FDA accepts IND application to initiate human clinical trial to evaluate BNC

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

FerroKin BioSciences initiates international Phase 2 study of FBS0701

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

Latest achievements in brain research and treatment for mental disorders

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Pittcon Highlights: Pharmaceutical & Biologic eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News